Work

Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia

Year: 2020

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2020-143473

Authors: Paula A. Lengerke Diaz, Michael Y. Choi, Eider F. Moreno Cortes, Jose V. Forero, Juliana Velez-Lujan, Carlos I. Amaya-Chanaga, Thomas Kipps, Januario E. Castro

Institutions: Mayo Clinic, Mayo Clinic in Arizona, University of California San Diego, Moores Cancer Center, Mayo Clinic Hospital, Eisai (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3096504021

FWCI:

Cites:

Cited by:

Related to: 10